Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alain Delmer

Showing results (91-100 of 109) with videos related to

Pageof 11
Sort By:
Haematologica|November 12, 2020
A prognostic index predicting survival in transformed Waldenström macroglobulinemiaEric Durot, Lukshe Kanagaratnam, Saurabh Zanwar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2024
Simplified Risk Stratification Model for Patients With Waldenström MacroglobulinemiaSaurabh Zanwar, Jennifer Le-Rademacher, Eric Durot, et al.
Haematologica|August 31, 2019
Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcriptionJennifer Edelmann, Karlheinz Holzmann, Eugen Tausch, et al.
Blood Advances|January 26, 2021
Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphomaFrançois Lemonnier, Violaine Safar, Asma Beldi-Ferchiou, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 20, 2019
Early <sup>18</sup>F-FDG PET/CT Response Predicts Survival in Relapsed or Refractory Hodgkin Lymphoma Treated with NivolumabAiping Chen, Fatima-Zohra Mokrane, Lawrence H Schwartz, et al.
Blood|April 19, 2018
A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapyEmmanuel Bachy, Matthew J Maurer, Thomas M Habermann, et al.
Lancet (London, England)|December 24, 2010
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trialGilles Salles, John Francis Seymour, Fritz Offner, et al.
The Lancet. Oncology|January 20, 2019
PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 studyRené-Olivier Casasnovas, Reda Bouabdallah, Pauline Brice, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2022
Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients Age 60 Years and Younger: Long-Term Results of the Randomized Phase II PRECIS StudyCaroline Houillier, Sylvain Dureau, Luc Taillandier, et al.
Blood Advances|April 7, 2023
A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trialAnne-Sophie Michallet, Rémi Letestu, Magali Le Garff-Tavernier, et al.
Pageof 11

Showing results (91-100 of 109) with videos related to

Sort By:
Pageof 11
Haematologica|November 12, 2020
A prognostic index predicting survival in transformed Waldenström macroglobulinemiaEric Durot, Lukshe Kanagaratnam, Saurabh Zanwar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2024
Simplified Risk Stratification Model for Patients With Waldenström MacroglobulinemiaSaurabh Zanwar, Jennifer Le-Rademacher, Eric Durot, et al.
Haematologica|August 31, 2019
Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcriptionJennifer Edelmann, Karlheinz Holzmann, Eugen Tausch, et al.
Blood Advances|January 26, 2021
Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphomaFrançois Lemonnier, Violaine Safar, Asma Beldi-Ferchiou, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 20, 2019
Early <sup>18</sup>F-FDG PET/CT Response Predicts Survival in Relapsed or Refractory Hodgkin Lymphoma Treated with NivolumabAiping Chen, Fatima-Zohra Mokrane, Lawrence H Schwartz, et al.
Blood|April 19, 2018
A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapyEmmanuel Bachy, Matthew J Maurer, Thomas M Habermann, et al.
Lancet (London, England)|December 24, 2010
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trialGilles Salles, John Francis Seymour, Fritz Offner, et al.
The Lancet. Oncology|January 20, 2019
PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 studyRené-Olivier Casasnovas, Reda Bouabdallah, Pauline Brice, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2022
Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients Age 60 Years and Younger: Long-Term Results of the Randomized Phase II PRECIS StudyCaroline Houillier, Sylvain Dureau, Luc Taillandier, et al.
Blood Advances|April 7, 2023
A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trialAnne-Sophie Michallet, Rémi Letestu, Magali Le Garff-Tavernier, et al.
Pageof 11